Cariprazine in an Adolescent with Tourette Syndrome with Comorbid Attention Deficit Hyperactive Disorder and Depression: A Case Report
Abstract
:1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Cavanna, A.E.; Rickards, H. The psychopathological spectrum of Gilles de la Tourette syndrome. Neurosci. Biobehav. Rev. 2013, 37, 1008–1015. [Google Scholar] [CrossRef]
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; American Psychiatric Association: Philadelphia, PA, USA, 2013. [Google Scholar] [CrossRef]
- Leckman, J.F. Tourette’s syndrome. Lancet 2002, 360, 1577–1586. [Google Scholar] [CrossRef] [PubMed]
- Leckman, J.F.; Zhang, H.; Vitale, A.; Lahnin, F.; Lynch, K.; Bondi, C.; Kim, Y.-S.; Peterson, B.S. Course of Tic Severity in Tourette Syndrome: The First Two Decades. Pediatrics 1998, 102, 14–19. [Google Scholar] [CrossRef] [PubMed]
- Hassana, N.; Cavanna, A.E. The prognosis of Tourette syndrome: Implications for clinical practice. Funct. Neurol. 2012, 27, 23. [Google Scholar]
- Knight, T.; Steeves, T.; Day, L.; Lowerison, M.; Jette, N.; Pringsheim, T. Prevalence of Tic Disorders: A Systematic Review and Meta-Analysis. Pediatr. Neurol. 2012, 47, 77–90. [Google Scholar] [CrossRef]
- Cavanna, A.E.; Critchley, H.D.; Orth, M.; Stern, J.S.; Young, M.B.; Robertson, M.M. Dissecting the Gilles de la Tourette spectrum: A factor analytic study on 639 patients. J. Neurol. Neurosurg. Psychiatry 2011, 82, 1320–1323. [Google Scholar] [CrossRef]
- Robertson, M.M. Mood disorders and Gilles de la Tourette’s syndrome: An update on prevalence, etiology, comorbidity, clinical associations, and implications. J. Psychosom. Res. 2006, 61, 349–358. [Google Scholar] [CrossRef]
- Chou, I.-C.; Lin, H.-C.; Lin, C.-C.M.; Sung, F.-C.; Kao, C.-H. Tourette Syndrome and Risk of Depression. J. Dev. Behav. Pediatr. 2013, 34, 181–185. [Google Scholar] [CrossRef]
- Khalifa, N.; VON Knorring, A.-L. Psychopathology in a Swedish Population of School Children with Tic Disorders. J. Am. Acad. Child Adolesc. Psychiatry 2006, 45, 1346–1353. [Google Scholar] [CrossRef]
- Rizzo, R.; Gulisano, M.; Calì, P.V.; Curatolo, P. Tourette Syndrome and comorbid ADHD: Current pharmacological treatment options. Eur. J. Paediatr. Neurol. 2013, 17, 421–428. [Google Scholar] [CrossRef]
- Eddy, C.M.; Rickards, H.E.; Cavanna, A.E. Treatment strategies for tics in Tourette syndrome. Ther. Adv. Neurol. Disord. 2011, 4, 25–45. [Google Scholar] [CrossRef] [PubMed]
- Padala, P.R.; Qadri, S.F.; Madaan, V. Aripiprazole for the treatment of Tourette’s disorder. Prim. Care Companion J. Clin. Psychiatry 2006, 7, 296–299. [Google Scholar] [CrossRef]
- Pringsheim, T.; Marras, C. Pimozide for tics in Tourette’s syndrome. Cochrane Database Syst. Rev. 2009, 2009, CD006996. [Google Scholar] [CrossRef] [PubMed]
- Scahill, L.; Leckman, J.; Schultz, R.; Katsovich, L.; Peterson, B. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003, 60, 1130–1135. [Google Scholar] [CrossRef]
- Gerasch, S.; Kanaan, A.S.; Jakubovski, E.; Müller-Vahl, K.R. Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome. Front. Neurosci. 2016, 10, 416. [Google Scholar] [CrossRef]
- Rickards, H.; Cavanna, A.E.; Worrall, R. Treatment practices in Tourette syndrome: The European perspective. Eur. J. Paediatr. Neurol. 2012, 16, 361–364. [Google Scholar] [CrossRef] [PubMed]
- Stahl, S.M. Mechanism of action of cariprazine. CNS Spectr. 2016, 21, 123–127. [Google Scholar] [CrossRef]
- Cutler, A.J.; Durgam, S.; Wang, Y.; Migliore, R.; Lu, K.; Laszlovszky, I.; Németh, G. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: Results from a 1-year open-label study. CNS Spectr. 2018, 23, 39–50. [Google Scholar] [CrossRef]
- Durgam, S.; Greenberg, W.M.; Li, D.; Lu, K.; Laszlovszky, I.; Nemeth, G.; Migliore, R.; Volk, S. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: Results from a 48-week, single-arm, open-label extension study. Psychopharmacology 2017, 234, 199–209. [Google Scholar] [CrossRef]
- Durgam, S.; Litman, R.E.; Papadakis, K.; Li, D.; Németh, G.; Laszlovszky, I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. Int. Clin. Psychopharmacol. 2016, 2, 61–68. [Google Scholar] [CrossRef]
- Kane, J.M.; Zukin, S.; Wang, Y.; Lu, K.; Ruth, A.; Nagy, K.; Laszlovszky, I.; Durgam, S. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results from an International, Phase III Clinical Trial. J. Clin. Psychopharmacol. 2015, 35, 367–373. [Google Scholar] [CrossRef] [PubMed]
- Stahl, S.M.; Laredo, S.; Morrissette, D.A. Cariprazine as a treatment across the bipolar I spectrum from depression to mania: Mechanism of action and review of clinical data. Ther. Adv. Psychopharmacol. 2020, 10. [Google Scholar] [CrossRef] [PubMed]
- Durgam, S.; Earley, W.; Guo, H.; Li, D.; Németh, G.; Laszlovszky, I.; Fava, M.; Montgomery, S.A. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: A randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J. Clin. Psychiatry 2016, 77, 371–378. [Google Scholar] [CrossRef]
- Fava, M.; Durgam, S.; Earley, W.; Lu, K.; Hayes, R. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: A randomized, double-blind, placebo-controlled trial. Int. Clin. Psychopharmacol. 2018, 33, 312–321. [Google Scholar] [CrossRef]
- Haas, M.; Jakubovski, E.; Fremer, C.; Dietrich, A.; Hoekstra, P.J.; Jäger, B.; Müller-Vahl, K.R.; EMTICS Collaborative Group. Yale Global Tic Severity Scale (YGTSS): Psychometric Quality of the Gold Standard for Tic Assessment Based on the Large-Scale EMTICS Study. Front. Psychiatry 2021, 12, 626459. [Google Scholar] [CrossRef] [PubMed]
- Roessner, V.; Eichele, H.; Stern, J.S.; Skov, L.; Rizzo, R.; Debes, N.M.; Nagy, P.; Cavanna, A.E.; Termine, C.; Ganos, C.; et al. European clinical guidelines for Tourette syndrome and other tic disorders—Version 2.0. Part III: Pharmacological treatment. Eur. Child Adolesc. Psychiatry 2022, 31, 425–441. [Google Scholar] [CrossRef]
- Durgam, S.; Earley, W.; Lipschitz, A.; Guo, H.; Laszlovszky, I.; Németh, G.; Vieta, E.; Calabrese, J.R.; Yatham, L.N. An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients with Bipolar I Depression. Am. J. Psychiatry 2016, 173, 271–281. [Google Scholar] [CrossRef]
- Earley, W.; Burgess, M.V.; Rekeda, L.; Dickinson, R.; Szatmári, B.; Németh, G.; McIntyre, R.S.; Sachs, G.S.; Yatham, L.N. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study. Am. J. Psychiatry 2019, 176, 439–448. [Google Scholar] [CrossRef]
- Kiss, B.; Horváth, A.; Némethy, Z.; Schmidt, É.; Laszlovszky, I.; Bugovics, G.; Fazekas, K.; Hornok, K.; Orosz, S.; Gyertyán, I.; et al. Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile. Experiment 2010, 333, 328–340. [Google Scholar] [CrossRef]
- McIntyre, R.S.; Daniel, D.G.; Vieta, E.; Laszlovszky, I.; Goetghebeur, P.J.; Earley, W.R.; Patel, M.D. The efficacy of cariprazine on cognition: A post hoc analysis from phase II/III clinical trials in bipolar mania, bipolar depression, and schizophrenia. CNS Spectr. 2022, 28, 319–330. [Google Scholar] [CrossRef]
- Miller, D.D. Atypical antipsychotics: Sleep, sedation, and efficacy. Prim. Care Companion J. Clin. Psychiatry 2004, 6 (Suppl. S2), 3. [Google Scholar] [PubMed]
- Barabássy, Á.; Sebe, B.; Acsai, K.; Laszlovszky, I.; Szatmári, B.; Earley, W.R.; Németh, G. Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies. Neuropsychiatr. Dis. Treat. 2021, 17, 957–970. [Google Scholar] [CrossRef] [PubMed]
- Tohen, M. Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data. Drug Des. Dev. Ther. 2021, 15, 2005–2012. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gill, J.S. Cariprazine in an Adolescent with Tourette Syndrome with Comorbid Attention Deficit Hyperactive Disorder and Depression: A Case Report. Healthcare 2023, 11, 2531. https://doi.org/10.3390/healthcare11182531
Gill JS. Cariprazine in an Adolescent with Tourette Syndrome with Comorbid Attention Deficit Hyperactive Disorder and Depression: A Case Report. Healthcare. 2023; 11(18):2531. https://doi.org/10.3390/healthcare11182531
Chicago/Turabian StyleGill, Jesjeet Singh. 2023. "Cariprazine in an Adolescent with Tourette Syndrome with Comorbid Attention Deficit Hyperactive Disorder and Depression: A Case Report" Healthcare 11, no. 18: 2531. https://doi.org/10.3390/healthcare11182531